Compare
Arcadia Biosciences, Inc. vs SRX Global Inc. vs Vita Coco Company, Inc. vs Keurig Dr Pepper Inc.
| Latest fiscal year | Arcadia Biosciences, Inc. RKDA | SRX Global Inc. SRXH | Vita Coco Company, Inc. COCO | Keurig Dr Pepper Inc. KDP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-09-30 | 2025-12-31 | 2025-12-31 |
| Revenue | $4.86M | $6.53M | $609.78M | $16.60B |
| Revenue growth (YoY) | -3.7% | n/a | +18.2% | +8.2% |
| Gross margin | 36.2% (computed) | 23.4% | 36.5% | 54.2% |
| Operating margin | -51.5% | -174.6% | 13.5% | 21.5% |
| Net margin | -48.1% | -688.8% | 11.7% | 12.5% |
| Net income | -$2.34M | -$45.01M | $71.32M | $2.08B |
| EPS (Diluted) | -$1.71 | -$2.13 | $1.19 | $1.53 |
| Operating cash flow | -$4.74M | -$8.14M | $47.17M | $1.99B |
| Free cash flow | -$4.74M | n/a | $39.02M | $1.50B |
| Cash & equivalents | $259.0K | $1.31M | $196.87M | $1.03B |
| Total assets | $6.55M | $8.40M | $461.16M | $55.46B |
| Total liabilities | $2.41M | $8.00M | $129.62M | $29.94B |
| Shareholders' equity | $4.14M | $407.0K | $331.54M | $25.52B |
| Return on year-end equity | -56.5% | n/m | 21.5% | 8.1% |
| Shares outstanding | 1.37M | 24.92M | 57.08M | 1.36B |
Revenue, most recent five fiscal years
| Fiscal year | Arcadia Biosciences, Inc. | SRX Global Inc. | Vita Coco Company, Inc. | Keurig Dr Pepper Inc. |
|---|---|---|---|---|
| Latest | $4.86M Ended 2025-12-31 | $6.53M Ended 2025-09-30 | $609.78M Ended 2025-12-31 | $16.60B Ended 2025-12-31 |
| 1 year earlier | $5.04M Ended 2024-12-31 | n/a | $516.01M Ended 2024-12-31 | $15.35B Ended 2024-12-31 |
| 2 years earlier | $4.45M Ended 2023-12-31 | n/a | $493.61M Ended 2023-12-31 | $14.81B Ended 2023-12-31 |
| 3 years earlier | $7.42M Ended 2022-12-31 | n/a | $427.79M Ended 2022-12-31 | $14.06B Ended 2022-12-31 |
| 4 years earlier | $6.78M Ended 2021-12-31 | n/a | $379.51M Ended 2021-12-31 | $12.68B Ended 2021-12-31 |